Anal Squamous Cell Carcinoma
Conditions
Brief summary
The proposed study is a phase II, single arm, open-label trial of MR-guided radiation therapy (RT) with risk stratified RT dose selection in patients with anal cancer. Based on previous data, a risk adaptive treatment approached is proposed in 4 groups: Low risk, standard risk, intermediate risk, and high risk. Human papillomavirus (HPV) DNA will be analyzed to identify novel biomarkers that predict chemoradiotherapy (CRT) response and toxicity.
Detailed description
After being informed about the study and potential risks, all patients giving written informed consent will undergo a risk-stratified dose of treatment (radiation dose and chemotherapy number of cycles) based on predefined clinical and biological biomarkers for anal squamous cell carcinoma (SCC). Radiotherapy will be delivered on the MR-Linac for image-guided-radiation therapy (IGRT). Patients will be followed for up to 5 years after radiotherapy and be required to complete questionnaires and clinic visits. Patients have the option to complete blood and tissue samples during the study.
Interventions
RADIATIONRadiotherapy - Low risk group
20 fractions completed in 4 weeks
RADIATIONRadiotherapy - Standard risk group
25 fractions completed in 5 weeks
RADIATIONRadiotherapy - Intermediate risk group
30 fractions completed in 6 weeks
RADIATIONRadiotherapy - High risk group
35 fractions completed in 7 weeks
Sponsors
University Health Network, Toronto
Medical College of Wisconsin
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with pathologically proven diagnosis of anal SCC. This may include tumors of non-keratinizing histology such as basoloid or cloacogenic histology. Individuals with squamous cell carcinoma of the anal margin are eligible. * Clinical stage T1-4 N0-1 M0 (the Union for International Cancer Control (UICC) / the American Joint Committee on Cancer (AJCC) 8th Ed) * Patients must be eligible for definitive RT or CRT * Must be ≥ 18 years of age * Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
Exclusion criteria
* Previous chemotherapy, RT or curative-intent surgical treatment (i.e. APR) for anal cancer. * Any previous RT to the abdomino-pelvic region that would result in overlap of RT volume for the current study. * Individuals with a history of a different malignancy except if they have been disease-free for at least 2 years and are deemed by the investigator to be at low risk for recurrence. Individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in locoregional failure (LRF) at Year 2 | 2 years | Any local or regional failure from the date of registration to the date of any of the local or regional failure. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Presence of distant metastasis (DM) | 5 years | Clear clinical/radiographic evidence of distant metastases in the lung, bone, brain, liver or other distant sites. |
| Colostomy rate | 5 years | The presence of a colostomy until colostomy removal. |
| Disease free survival (DFS) | 5 years | The time from the date of registration to the date of first record of any of the following events including local, regional, distant failure, or death due to any cause. |
| Overall survival (OS) | 5 years | The time from the date of registration to the date of death for any cause. |
| Physician-reported toxicities | 5 years | Using the National Cancer Institute (NCI) Common Terminology Criteria of Adverse Events (CTCAE) V.5. |
| Patient Reported Outcomes | 5 years | Using the Common Terminology Criteria of Adverse Events |
| Quality of life (QOL) | 5 years | Based on the completion of the European Organisation For Research And Treatment Of Cancer (EORTC-C30) questionnaire. The EORTC-C30 questionnaire is a 30 item instrument meant to assess some of the different aspects that define the quality of life of cancer patients. |
Countries
Australia, Canada, United States
Contacts
CONTACTAli Hosni
Outcome results
None listed